MedTrace Logo

Decision to Limit or Withdraw Specific Therapies for Advanced Cancer and Hematological Malignancies.

NCT02841124 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2016-07-27

No results posted yet for this study

Summary

The decision to limit or withdraw specific therapies (DLWT) in patients with advanced cancer is a complex process that is always painful for patients, relatives and professionals. For more than 10 years, shared decision making has been more and more emphasized. However, few data in the literature rely on clinical research. In order to understand their difficulties and issues, this study explores the determinants and modalities of DLWT and analyses the feasibility of different methods for investigating this decision making process.

Conditions

Interventions

OTHER

interviews

face-to-face interviews with the referent oncologist (or hematologist) and his patient (conducted by a physician and a psychologist respectively) as well as interviews with other partners involved in the situation (care staff and relatives)

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Saint Antoine, Paris

    collaborator UNKNOWN

  • Centre de Lutte Contre le Cancer Alexis Vautrin, Vandoeuvre les Nancy

    collaborator UNKNOWN

  • Centre Hospitalier de Colmar

    collaborator OTHER

  • Clinique Devron, Dijon

    collaborator UNKNOWN

  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02841124 on ClinicalTrials.gov